| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
173 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
16 |
| Net Income (TTM) (Millions $) |
-121 |
| Cash Flow (TTM) (Millions $) |
-37 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Kadmon Holdings Inc is a biopharmaceutical company that focuses on discovering, developing, and commercializing innovative therapies for unmet medical needs. The company's primary areas of research and development include oncology, autoimmune and inflammatory diseases, and genetic diseases.
Kadmon's pipeline includes both small molecule and biologics candidates, targeting various diseases such as acute myeloid leukemia, solid tumors, graft-versus-host disease, and immune disorders. Their lead product candidate, belumosudil, is being investigated for the treatment of chronic graft-versus-host disease and other diseases involving fibrosis.
The company also has a portfolio of marketed products that are focused on rare diseases, including Reblozyl for the treatment of anemia in patients with beta thalassemia and refractory anemia with ring sideroblasts, and Rizmoic for the treatment of chronic graft-versus-host disease-related gastrointestinal disorders.
Kadmon's strategic focus is on advancing its pipeline, developing partnerships, and expanding its commercial presence globally. The company aims to bring new and effective therapies to patients in need while driving long-term shareholder value.
Company Address: 450 East 29th Street New York 10016 NY
Company Phone Number: 900-5366 Stock Exchange / Ticker: NASDAQ KDMN
|
%
